Dengue 1,2,3,4 (attenuated) vaccine

BIOLOGICAL4 trials

Conditions

Antiphospholipid SyndromeAxial SpondyloarthritisDengueGranulomatosis With PolyangiitisIdiopathic Inflammatory Myopathies (IIMs)Juvenile Idiopathic Arthritis (JIA)Juvenile Systemic Lupus ErythematosusMicroscopic Polyangiitis

Phase 2

Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine

NCT01696422

Butantan InstituteDengue

Start: 2013-10-31End: 2020-12-31Updated: 2019-01-16

Phase 3

Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine

Active, not recruitingNCT02406729

Butantan InstituteDengue

Start: 2016-02-22End: 2024-11-30Target: 16935Updated: 2024-02-15

Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)

RecruitingNCT06891950

Butantan InstituteDengue

Start: 2026-03-03End: 2027-10-01Target: 997Updated: 2026-07-16

Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

RecruitingNCT07087912

University of Sao Paulo General HospitalAntiphospholipid Syndrome, Axial Spondyloarthritis, Granulomatosis With Polyangiitis +9

Start: 2026-03-16End: 2028-12-30Target: 477Updated: 2026-07-20

2026-03-04

Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine.

2025-10-14

Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil.

2024-08-0524 citations

Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults

New England Journal of Medicine2024-01-31146 citations

Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine

BMC Infectious Diseases2023-05-232 citations

Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort

Frontiers in Immunology2022-06-284 citations

Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.

2020-03-2469 citations

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico

American Journal of Tropical Medicine and Hygiene2018-03-0643 citations

Dengue 1,2,3,4 (attenuated) vaccine

Sponsors

Conditions

Phase 2

Phase 3

Phase 4

Related Papers